GENEA022
GENEAe016-A
General
Donor Information
General Donor Information |
|
| Sex | male |
Phenotype and Disease related information (Donor) |
|
| Diseases | No disease was diagnosed.
|
Donor Relations |
|
| All cell lines of this donor's relatives |
Has brother:
Has brother:
|
External Databases (Donor) |
|
| BioSamples | SAMEA104130952 |
Ethics
| Was the embryo established purely for research purposes? | No |
| Have both parents consented to the use of the embryo for ESC derivation? | Yes |
| Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | Yes |
| Was the consent voluntarily given? | Yes |
| Has the donor been informed that participation will not directly influence their personal treatment? | Yes |
| Can you provide us with a copy of the Donor Information Sheet provided to the donor? | Yes |
| Do you (Depositor/Provider) hold the original Donor Consent Form? | Yes |
| Alternatives to consent are available? | Yes |
| Alternatives to consent | Genea022 ( outgrowth cells from a sibling embryo to Genea021&GENEA023) was derived from embryonic outgrowth cells, originally developed for karyotyping, not from the embryo with fully informed consent.only one document can be added here so other document will be emailed. |
| Alternative consent approval number | |
| Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. | pseudonymised |
| Does consent explicitly allow the derivation of pluripotent stem cells? | Yes |
| Does consent expressly prevent the derivation of pluripotent stem cells? | No |
| Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
| How may genetic information associated with the cell line be accessed? | No information |
| Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? | No |
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? | Yes |
| Name of accrediting authority involved? | GENEA HREC |
| Approval number | Meeting 13/9/2005 |
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the PROPOSED PROJECT, involving use of donated embryo/tissue or derived cells? | Yes |
| Name of accrediting authority involved? | GENEA HREC |
| Approval number | Meeting 13/9/2005 |
hESC Derivation
| Date of derivation | 2008-8-18 |
| Supernumerary embryos from IVF treatment? |
Yes
Separation of research and IVF treatment?
Yes |
| PGD Embryo? |
Yes |
Culture Conditions
| Medium |
Other medium:
Base medium: KO-DMEM
Main protein source: Knock-out serum replacement Serum concentration: 20 % Supplements
|
Characterisation
Analysis of Undifferentiated Cells
| Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
| NANOG |
Yes |
|||||
| POU5F1 (OCT-4) |
Yes |
|||||
| SSEA-4 |
Yes |
|||||
| TRA 1-60 |
Yes |
| Pluripotency Score | Novelty Score | |
| 42.95 | 1.23 |
Teratoma positive, Alkaline Phosphatase stain positive.
Differentiation Potency
Genotyping
Karyotyping (Cell Line) |
|
| Has the cell line karyotype been analysed? |
Yes
46, XY no abnormalities detected
Passage number: 38
|
Other Genotyping (Cell Line) |
|
Login to share your feedback, experiences or results with the research community.